Discover startups, services, products and more from our partner StackCommerce. New York Post may be compensated and/or receive an affiliate commission if you...
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...